Clinical Trial Imaging Market to Reach $1.31 Billion by 2026 | Grand View Research

The global Clinical Trial Imaging Market size is expected to reach USD 1.31 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.8% during the forecast period. Increasing spending on research and development activities to develop new drugs and therapies to treat chronic diseases is boosting market growth.

Clinical trials assist in the development, registration, and eventually access of new drugs to patients. Imaging helps in the process of drug development by offering non-invasive evaluation of drug action and response of tumor to treatment. Functional imaging techniques are progressively being used in early phases of clinical trials to study initial effects of drug action on parts of tumor biology including metabolism, cellularity, and vascularity. 

Contract Research Organizations (CROs) were the most prominent end-use segment in the market in 2017. Imaging modalities are used to determine indicators of pharmacological response to a therapy. Biomarkers and surrogate endpoints assist in obtaining quick results with good statistical power even in small sample sizes encouraging CROs to carryout multiple studies with reduced cost of operation.

The market in Asia Pacific is projected to witness swift growth during the forecast period as the number of CROs and pharmaceutical organizations in the region are increasing in recent past due to low cost of labor and public and private funding offered in countries such as India and China. However, inaccessibility of trial protocols and poor quality of registered clinical trial data, results, and participant-level data undermined the potential benefits of clinical trial registration earlier. Nevertheless, emergence of national and regional registries and ICTRP have facilitated to overcome aforementioned barriers in APAC.

Further key findings from the report suggest

  • North America dominated the market in 2017. Attaining compliance with registration requires a combination of international and local measures and remains a key challenge in many countries. However, U.S. FDA and other regulatory organizations have played a leading role in attaining accomplishments of trial registration to date and is likely to be supported in tackling such challenges in the near future
  • Some of the players operating in this market are Parexel International Corporation; Intrinsic Imaging; Radiant Sage; Icon PLC; Worldcare Clinical; Bioclinica Inc.; Navitas Life Sciences; Resonance Health; Ixico PLC; and Medpace.

Browse Details of Report @

Showing 1 reaction

Please check your e-mail for a link to activate your account.